soul study semaglutide cardiovascular outcomes news today 2025 trial oral results in High- Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial Shows Oral Semaglutide – Semaglutide 2.4 mg delivered a – The impact of oral semaglutide

Steen Hvass Ingwersen is employed by and holds stocks in Novo Nordisk A/S

Discover science-backed insights and expert guidance to optimize your health, achieve sustainable weight loss, and unlock your body's natural vitality

Viking Therapeutics (VKTX): The pure-play GLP-1 development company reported promising Phase 2 data for its own obesity candidate, VK2735

Discuss all options with your provider including manufacturer savings programs, compounded formulations , and more affordable alternatives

Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans

Clinical trials have highlighted its potential, showing average weight loss of 15% to 20% when coupled with lifestyle changes, affirming its position as a leading weight loss medication